Raymond James & Associates Karyopharm Therapeutics Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$12.0 - $19.88 $137,076 - $227,089	-11,423 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$9.92 - $17.25 $82,445 - $143,364	-8,311 Reduced 42.12%	11,423 $153,000
Q4 2017 Feb 14, 2018	BUY	$9.15 - $11.99 $15,930 - $20,874	1,741 Added 9.68%	19,734 $189,000
Q3 2017 Nov 13, 2017	SELL	$8.15 - $11.16 $164,426 - $225,153	-20,175 Reduced 52.86%	17,993 $198,000
Q2 2017 Aug 14, 2017	BUY	N/A	38,168	38,168 $345,000

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $67.8M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.